Results 231 to 240 of about 111,871 (303)

Adequacy evaluation of 22‐gauge needle endoscopic ultrasound‐guided tissue acquisition samples and glass slides preparation for successful comprehensive genomic profiling testing: A single institute experience

DEN Open, Volume 6, Issue 1, April 2026.
Abstract Objectives This study aimed to evaluate the successful sequencing rate of Foundation One CDx (F1CDx) using small tissue samples obtained with a 22‐gauge needle (22G) through endoscopic ultrasound‐guided fine needle acquisition (EUS‐TA) and to propose guidelines for tissue quantity evaluation criteria and proper slide preparation in clinical ...
Tami Nagatani, Yoji Wani, Masahiro Takatani, Soichiro Fushimi, Hirofumi Inoue, Shinichiro Hori, Kyohei Kai, Hideki Yamamoto, Tetsuya Okazaki, Maki Tanioka, Hiroyuki Okada, Akira Hirasawa   +11 more
wiley   +1 more source

The Real-World Impact of PARP Inhibitor Maintenance Therapy in High Grade Serous Tubo-Ovarian and Peritoneal Cancers. [PDF]

Cancers (Basel)
Al-Ani M, Baraka B, Mathiyalagan N, Sarwar MA, Segaran A, Abuzahra W, Radford A, Buxton K, Seneviratne L, Sundar S, Anand A, Nunns D, Williamson K, Wormald B, Gajjar K, Madhusudan S.   +15 more
europepmc   +1 more source

Patient and Public Involvement Reporting Consistency: Analysis of 24 Clinical Practice Guidelines From 4 Countries

Clinical and Public Health Guidelines, Volume 3, Issue 2, April 2026.
ABSTRACT Objective We compared the reporting of patient and public involvement (PPI) in the development of clinical practice guidelines (CPG) with the guidance regarding PPI in the auspicing organisation's guideline development manual. Methods We examined the PPI guidance provided by seven guideline auspicing organisations from four countries, that ...
Elizabeth Ann Bryant, Rae Thomas, Sharon Lea Sanders   +2 more
wiley   +1 more source

DNA Methylation in Ovarian and Endometrial Cancers: Predictive and Mechanistic Roles in PARP Inhibitor and ICI Response. [PDF]

Cancer Sci
Kitamura S, Taguchi A, Tamai K, Yamamoto Y, Duong AQ, Yoshimoto D, Mori A, Ishizaka A, Tsuchimochi S, Sone K, Kawazu M, Oda K, Hirota Y.   +12 more
europepmc   +1 more source

Clinical Discovery and Molecular Analysis of Two Novel MSH2 Gene Mutations (p.Ala771Gly and p.Val797Gly) in Saudi Colorectal Cancer Patients: Potential Implications for Tumorigenesis

Health Science Reports, Volume 9, Issue 4, April 2026.
ABSTRACT Background and Aims Colorectal cancer (CRC) is a serious global health problem, ranking first in men and third in women among all cancers worldwide. The genetic basis for CRC remains unclear in most cases; therefore, the present study aimed to investigate the molecular genetic basis of CRC and correlate it with disease outcomes.
Mahmood Rasool, Absarul Haque, Mohammed Alharthi, Tainus Ali, Sajjad Karim, Loubna Siraj Mira, Fahd Al‐Abbasi, Murad Aljiffry, Mohammed Ghunaim, Abdulrahman Sibiany, Peter Natesan Pushparaj   +10 more
wiley   +1 more source

Therapeutic Potential of Metal-Based and PARP Inhibitor Chemotherapy for <i>BRCA1</i>-Associated Triple-Negative Breast Cancer. [PDF]

Int J Mol Sci
Ratanaphan A.
europepmc   +1 more source

Optimizing the integration of modern systemic therapies and advanced radiotherapy techniques in breast cancer management: An expert opinion from the Institut Curie Breast Radiotherapy Group

International Journal of Cancer, Volume 158, Issue 7, Page 1775-1784, 1 April 2026.
Abstract The integration of modern systemic therapies with radiotherapy (RT) represents a promising strategy in breast cancer management, enhancing both locoregional control and systemic disease outcomes. This expert consensus from the Institut Curie Breast Radiotherapy Group focuses exclusively on modern systemic agents, synthesizing current evidence ...
Cezara Cheptea, Pierre Loap, Sofiane Allali, Alain Fourquet, Kim Cao, Youlia Kirova   +5 more
wiley   +1 more source

Real-world outcomes following PARP inhibitor maintenance in ovarian cancer by <i>BRCA</i> status: a retrospective cohort study. [PDF]

ESMO Real World Data Digit Oncol
Zucker K, Pickwell-Smith B, Samani A, Sujenthiran A, Pittell H, Mpofu P, Hall G.   +6 more
europepmc   +1 more source

Anti‐Cancer Effect of a New 5‐FU Derivative Containing Triazole‐Bearing Mannose (5‐FUD‐MAN) Against Human Breast Cancer Cells Through LC3B‐Mediated Cell Death

Journal of Biochemical and Molecular Toxicology, Volume 40, Issue 4, April 2026.
The anticancer activity of 5‐FU modified with mannose containing 1,2,3‐triazole compound in MCF‐7 breast cancer cells were revealed in this study. While 5‐FU caused cytotoxicity in both cancerous and healthy cells, 5‐FUD‐Man showed selective cytotoxicity.
Ebru Şanci, Azada Aliyeva, Buket Bakan, Mustafa Özkaraca, Erkan Halay, Kadir Ay, Tamer Karayildirim, N. Ulku Karabay Yavasoglu   +7 more
wiley   +1 more source

Characterization of Parthanatos in Breast Cancer: Implications for Prognosis and PARP Inhibitor Resistance. [PDF]

Bioengineering (Basel)
Tang J, Liu Q, Du W, Chen L, Qi F, Zhang R, Hoang BH, Geller DS, Yang R, Wang J, Hu L.   +10 more
europepmc   +1 more source